NASDAQ · MTSR
Metsera, Inc.
$70.50 -$0.25 (-0.35%) 1DKey Metrics
$7.46B
Market cap
—
P/E · TTM
—
Revenue · TTM
—
Net income
EPS · TTM
—
Dividend yield
—
Free cash flow
—
Beta · 1Y
—
EBITDA · TTM
—
Gross margin
—
Snapshot
Market cap$7.46B
Enterprise value—
Shares outstanding105.2M
52-wk range$28.91 – $83.86
Avg volume · 20D1.7M
Net cash
—
Book value / share$3.20
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Metsera, Inc.
IPO dateJan 31, 2025
Employees109
Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E—
P/S—
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №—
Profitability
Gross
—
Operating
—
Net
—
FCF
—
ROE / ROIC
— · —
Financial Health
Current ratio4.25
Quick ratio—
Debt / equity—
Debt / EBITDA
—
Net cash
—
Working capital$352.92M
Cash Flow · TTM
Operating CF
—
Capex
—
Free cash flow
—
Buybacks
—
Dividends paid
—
Shareholder yield
—
Piotroski F-Score
—
Needs two fiscal years of filings
Altman Z-Score
—
Insufficient balance-sheet inputs
Graham Number vs Price
—
Requires positive earnings and book value
Fundamentals through 2025-09-30 · computed by TickerWolf from SEC filings